BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Positron Corporation (POSC) Receives U.S. Patent for Solid State Sensors


10/16/2012 10:50:40 AM

CHICAGO, Oct. 16, 2012 /PRNewswire/ -- Positron Corporation announced today that the United States Patent and Trademark Office (USPTO) has awarded the Company a patent (U.S. No. 8,269,181) for its original semiconductor detector used in high precision measuring of coordinates and detection of ionization particles. The technology and patent issuance was achieved through collaboration with Dr. Valeri Saveliev of DESY in Hamburg, Germany. Dr. Saveliev's expertise in avalanche pixel sensors and related methods were instrumental in the development of the solid state technology.

The detector structure has two collinear layers of avalanche microcells with high internal amplification and is capable of detecting low energy ionization particles by overcoming a fundamental limitation of the precision coordinate measuring of ionization particlesmultiple scattering in material. The detector is not sensitive to photons and completely eliminates the dark rate as background.

Due to a high signal to noise ratio, the detection and coordinate measuring can be achieved on a chip without special on-chip readout electronics and/or additional external electronics, which can significantly reduce the cost of the detection or imaging equipment. The detector is small, robust, and operates at an extremely low voltage.

The detector has a number of potential applications in medical imaging, radiotherapy (photon therapy, electron therapy, hadron therapy), homeland security, experimental physics, and Auger electrons dosimeters.

"Positron's patented technology makes it possible to provide radiotherapy systems at a lower cost with an increased precision of treatment, thus limiting the damage to normal tissue. This technology will also provide a less expensive, much smaller detector, with an increased capability to localize the source(s) of ionizing radiation, for Homeland Security. This technology may be very valuable in the future for Positron as we continue to add value to our product portfolio. Positron is proud to have shared in this collaboration and to be associated with such a highly respected scientist as Dr. Saveliev," stated Patrick Rooney, Positron's chief executive officer.

About Positron: Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiologyproviding an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->